A novel SLTM::RUNX1 acquired during CML progression and the clinical significance of concurrent BCR::ABL1 and RUNX1 rearrangements in Ph-positive leukemia.
文献摘要
Introduction In leukemia class I alterations drive cellular proliferation whereas class II alterations block hematopoietic cell differentiation. Although these two types of alterations are associated with distinct morphology, clinical presentation, and outcome, they can be presented concurrently in rare cases. Clinical and genetic analysis of this group provides insight into synergistic impact of class I and class II on disease biology and clinical outcome. Here we molecularly dissected a t(15;21) and identified a new partner to RUNX1 in a chronic myeloid leukemia (CML) patient. We further evaluated the clinical outcome in leukemia patients with concurrent t(9;22)/BCR::ABL1 and 21q22 /RUNX1 rearrangement. Methods Bone marrow (BM) and/or peripheral blood (PB) at diagnosis and during disease progression was evaluated by morphology, flow cytometry, karyotype analysis, fluorescence in situ hybridization (FISH), next generation sequencing (NGS), and expression to determine genomic alterations at diagnosis and disease progression and their prognosis. Leukemia cases with concurrent t(9;22)/BCR::ABL1 and 21q22/RUNX1 rearrangement were retrieved from Mittelman's database. Each publication was curated and reviewed for information regarding treatment and outcome and the data was analyzed for their clinical impact in this group of patients. Results At presentation the patient has Ph-positive CML at chronic phase (CP) [t(9;22)(q34;q11.2)/BCR::ABL1 (p210 transcript) by FISH, PCR and NGS. Response to tyrosine kinase inhibitor (TKI - imatinib) treatment was suboptimal and the disease progressed to accelerated phase (AP). Karyotype at AP acquired a t(15;21)(q22;q22), RUNX1 rearrangement detected by FISH, an ABL1 kinase mutation (p.G250E, VAF 11.8%) and SLTM::RUNX1 by NGS. Thus, at this clinical stage patient had class I and class II alterations in leukemia cells. Over the course of the disease, patient underwent treatment with imatinib, dasatinib, bosutinib, and asciminib with failure to achieve major molecular response (MMR). The patient proceeded with intensive chemotherapy + ponatinib when the disease evolved into CML-blast phase (BP), followed by allogeneic hematopoietic stem cell transplantation and is now in complete molecular remission. Genetic and clinical outcome data of published cases of Ph-positive leukemia (CML, AML, ALL) patients with concurrent 21q22/RUNX1 alteration showed decreased survival if both alterations were present at CP and in a simple karyotype in CML. Conclusions Leukemia cases with concurrent class I and class II alteration form unique genetic group with tumorigenic alterations involved in independent cellular processes. CML patients with concurrent BCR::ABL1 and RUNX1 rearrangement at CP and a simple karyotype had poorer outcome. Furthermore, treatment with TKI and chemotherapy followed by bone marrow transplantation may have favorable outcome in selected group of patients. However, the treatment in these patients is heterogenous and therefore warrant further evaluation. The case here illustrates that in depth analysis of novel chromosome alterations unravel underlying pathogenetic pathways in disease progression. Accumulating information from such individual cases is important to further development of precision treatment tools in unique patients.